Hengrui Medicine begins share buyback, announces new drug trial approval

Jiangsu Hengrui Medicine Co., Ltd. initiated its first A-share repurchase, acquiring 270,000 shares on September 4, 2025, at prices ranging from CNY 67.75 to CNY 67.97 per share, totaling CNY 18,313,920. This marks the beginning of a larger program, approved on August 20, 2025, to repurchase between CNY 1,000,000,000 and CNY 2,000,000,000 worth of shares over 12 months, for employee stock ownership plans.

Concurrently, the company announced on September 4, 2025, that the National Medical Products Administration has approved clinical trials for HRS-4729 Injection. This multi-target drug, an independently developed polypeptide, is indicated for metabolic-associated fatty liver disease/metabolic-associated steatohepatitis. The total R&D investment for HRS-4729 Injection to date is approximately CNY 3,962,000. No similar products have been approved for market yet.